VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
405.7 EUR
-9.4 (-2.26%)
Taking everything into account, VX1 scores 6 out of 10 in our fundamental rating. VX1 was compared to 83 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes VX1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year VX1 was profitable.
In the past year VX1 had a positive cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a better Return On Assets (14.78%) than 87.95% of its industry peers.
VX1's Return On Equity of 21.22% is amongst the best of the industry. VX1 outperforms 91.57% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 92.77% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
VX1 has a Profit Margin of 31.35%. This is amongst the best in the industry. VX1 outperforms 87.95% of its industry peers.
VX1 has a better Operating Margin (38.70%) than 93.98% of its industry peers.
VX1's Operating Margin has improved in the last couple of years.
VX1's Gross Margin of 86.28% is fine compared to the rest of the industry. VX1 outperforms 78.31% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
VX1 has less shares outstanding than it did 1 year ago.
VX1 has less shares outstanding than it did 5 years ago.
VX1 has a better debt/assets ratio than last year.
2.2 Solvency
There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.78
WACC8.82%
2.3 Liquidity
VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VX1 (2.36) is comparable to the rest of the industry.
A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
With a Quick ratio value of 2.00, VX1 perfoms like the industry average, outperforming 45.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3303.92%, which is quite impressive.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.33% in the last year.
Measured over the past years, VX1 shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
The Earnings Per Share is expected to grow by 150.51% on average over the next years. This is a very strong growth
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.75% yearly.
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.51%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 27.21, which means the current valuation is very expensive for VX1.
Based on the Price/Earnings ratio, VX1 is valued a bit cheaper than 79.52% of the companies in the same industry.
VX1's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.19.
A Price/Forward Earnings ratio of 23.10 indicates a rather expensive valuation of VX1.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 81.93% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (23.92), we can say VX1 is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.21 | ||
| Fwd PE | 23.1 |
4.2 Price Multiples
VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 77.11% of the companies in the same industry.
VX1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VX1 is cheaper than 83.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.91 | ||
| EV/EBITDA | 23.97 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VX1 may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.89% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y739.72%
EPS Next 3Y328.89%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (1/9/2026, 7:00:00 PM)
405.7
-9.4 (-2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap102.93B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.92
Price Target425.31 (4.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)-1.13%
PT rev (3m)1.66%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)3.36%
EPS NY rev (1m)0.02%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.21 | ||
| Fwd PE | 23.1 | ||
| P/S | 10.22 | ||
| P/FCF | 35.91 | ||
| P/OCF | 32.23 | ||
| P/B | 6.92 | ||
| P/tB | 7.58 | ||
| EV/EBITDA | 23.97 |
EPS(TTM)14.91
EY3.68%
EPS(NY)17.56
Fwd EY4.33%
FCF(TTM)11.3
FCFY2.78%
OCF(TTM)12.59
OCFY3.1%
SpS39.69
BVpS58.63
TBVpS53.49
PEG (NY)0
PEG (5Y)N/A
Graham Number140.25
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.82%
ROIC/WACC1.78
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.51%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.75%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year811.13%
EBIT Next 3Y128.24%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.
What is the valuation status for VX1 stock?
ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
How financially healthy is VERTEX PHARMACEUTICALS INC?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.
What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 6343.89% in the next year.